Somewhat Positive Media Coverage Somewhat Unlikely to Affect Roka Bioscience (ROKA) Share Price
News headlines about Roka Bioscience (NASDAQ:ROKA) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Roka Bioscience earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned media stories about the medical research company an impact score of 45.4149553090222 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Roka Bioscience (NASDAQ:ROKA) remained flat at $$1.00 on Friday. The company’s stock had a trading volume of 138,427 shares, compared to its average volume of 331,758. Roka Bioscience has a 1 year low of $0.66 and a 1 year high of $6.20.
In other news, major shareholder Orbimed Advisors Llc sold 127,601 shares of the company’s stock in a transaction on Wednesday, September 27th. The stock was sold at an average price of $0.98, for a total value of $125,048.98. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 803,894 shares of company stock worth $603,915 over the last 90 days. Company insiders own 29.20% of the company’s stock.
Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.
Receive News & Ratings for Roka Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.